Literature DB >> 24666752

Metabolic profile of the different phenotypes of polycystic ovary syndrome in two Latin American populations.

Amanda Ladrón de Guevara1, Carolina Fux-Otta2, Nicolás Crisosto1, Paula Szafryk de Mereshian2, Bárbara Echiburú1, Gabriel Iraci3, Francisco Perez-Bravo4, Teresa Sir-Petermann5.   

Abstract

OBJECTIVE: To evaluate the metabolic profile of Chilean and Argentinian women with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria.
DESIGN: Observational cross-sectional study.
SETTING: Academic centers. PATIENT(S): Women with PCOS, aged 18-39 years: 220 Chilean (PCOSCh) and 206 Argentinian (PCOSAr). INTERVENTION(S): Physical examination, fasting blood samples for androgens, gonadotropins, metabolic parameters, and a transvaginal ultrasound. MAIN OUTCOME MEASURE(S): Comparative analysis of the metabolic profile in both populations divided into four phenotypes. RESULT(S): The distribution of the different phenotypes was different in both populations. PCOSCh women showed a higher body mass index and a higher percentage of metabolic syndrome in all phenotypes compared with the PCOSAr women. The PCOSAr women exhibited a statistically significantly higher diastolic blood pressure in phenotypes A, B, and C and a higher percentage of hypertension in phenotypes A and D compared with the PCOSCh women. CONCLUSION(S): The data show differences in the metabolic profile of both populations. PCOSCh women presented with greater metabolic alterations such as dysglycemia and dyslipidemia and a higher prevalence of metabolic syndrome, independent of the phenotype. The PCOSAr patients showed more elevated blood pressure. Ethnic diversity associated with environmental factors are fundamental elements in the analysis of the PCOS phenotypes.
Copyright © 2014 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Argentina; Chile; Rotterdam phenotypes; metabolic syndrome; polycystic ovary syndrome

Mesh:

Substances:

Year:  2014        PMID: 24666752     DOI: 10.1016/j.fertnstert.2014.02.020

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  6 in total

Review 1.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Authors:  Robert L Rosenfield; David A Ehrmann
Journal:  Endocr Rev       Date:  2016-07-26       Impact factor: 19.871

2.  Should All Women with Polycystic Ovary Syndrome Be Screened for Metabolic Parameters?: A Hospital-Based Observational Study.

Authors:  Hui Li; Lin Li; Jian Gu; Yu Li; Xiaoli Chen; Dongzi Yang
Journal:  PLoS One       Date:  2016-11-30       Impact factor: 3.240

3.  Ameliorative effects of rutin against metabolic, biochemical and hormonal disturbances in polycystic ovary syndrome in rats.

Authors:  Sarwat Jahan; Faryal Munir; Suhail Razak; Anam Mehboob; Qurat Ul Ain; Hizb Ullah; Tayyaba Afsar; Ghazala Shaheen; Ali Almajwal
Journal:  J Ovarian Res       Date:  2016-12-07       Impact factor: 4.234

Review 4.  Oxidative Stress and Low-Grade Inflammation in Polycystic Ovary Syndrome: Controversies and New Insights.

Authors:  Antonio Mancini; Carmine Bruno; Edoardo Vergani; Claudia d'Abate; Elena Giacchi; Andrea Silvestrini
Journal:  Int J Mol Sci       Date:  2021-02-07       Impact factor: 5.923

5.  Modulation of steroidogenesis by Actaea racemosa and vitamin C combination, in letrozole induced polycystic ovarian syndrome rat model: promising activity without the risk of hepatic adverse effect.

Authors:  Asmaa A Azouz; Sara E Ali; Reham M Abd-Elsalam; Shimaa R Emam; Mona K Galal; Sherif H Elmosalamy; Muhammed A Alsherbiny; Bardes B Hassan; Chun Guang Li; Shymaa A El Badawy
Journal:  Chin Med       Date:  2021-04-29       Impact factor: 5.455

6.  Metabolic Features of Women With Polycystic Ovary Syndrome in Latin America: A Systematic Review.

Authors:  Lucas Bandeira Marchesan; Ramon Bossardi Ramos; Poli Mara Spritzer
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-19       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.